EGFR and lung carcinoma: For example, Linc00152 promotes GC growth through activation of the epidermal growth factor receptor (EGFR)-dependent PI3K/Akt pathway [40]; lncRNA BC087858 induces lung cancer invasion and drug resistance to EGFR through activation of the PI3K/Akt pathway [41]; and MALAT1 accelerates cholangiocarcinoma progression through activation of the PI3K/Akt pathway [42].